UBS Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $22
Sabra Health Care REIT Is A Buy After Q3 Shows More Portfolio Expansion
Sabra Health Care REIT, Inc. 2026 Q3 - Results - Earnings Call Presentation
Sabra Health Care REIT (SBRA) Stock Looks Overvalued As Its 107% Five Year Run Continues
Sabra Health Care: 3 Key Takeaways for Long-Term Investors
Sabra Health Care REIT Inc (SBRA) (Q3 2026) Earnings Call Highlights: Strong SHOP Growth and ...
What Sabra Healthcare REIT (SBRA) Said on Its Q3 Earnings Call
Sabra Health (SBRA) Q3 2026 Earnings Call Transcript
Sabra Health Care REIT, Inc. (SBRA) Q3 2026 Earnings Call Transcript
Sabra Health Care REIT Q3 2026 Earnings Call Transcript
Sabra Health Care REIT, Inc. Q3 2026 Earnings Call Summary
Sabra: Q3 Earnings Snapshot
Sabra Health Care REIT (NASDAQ:SBRA) Tops Q3 2026 Estimates as SHOP Growth Drives Raised Guidance
Sabra Healthcare (SBRA) Tops Q3 FFO and Revenue Estimates
Sabra Reports Third Quarter 2026 Results; Updates 2026 Guidance
Sabra Health Care REIT Raises FY2026 FFO Guidance from $1.53-$1.55 to $1.54-$1.55 vs $1.55 Est
Sabra Health Care REIT Q3 FFO $0.39, Inline, Sales $249.565M Beat $232.392M Estimate
Sabra Health Care REIT, Inc. Announces Third Quarter 2026 Earnings Release Date and Conference Call
Wells Fargo Maintains Overweight on Sabra Health Care REIT, Lowers Price Target to $21
UBS Maintains Neutral on Sabra Health Care REIT, Lowers Price Target to $20
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.